Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 248

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 248
---
 and cash equivalents, and anticipated interest income, will not enable it to complete its development of CogniMIR.
DiamiR’s forecast of the period of time through which its financial resources will be adequate to support its operations is a forward-looking
statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors
discussed in the section entitled “Risk Factors” and elsewhere in this prospectus. DiamiR has based this estimate on assumptions
that may prove to be wrong, and it could utilize its available capital resources sooner than currently expected.

DiamiR’s future funding
requirements, both near- and long-term, will depend on many factors, including, but not limited to:

| ● | the initiation, progress, timing, costs, and results                                                                
 of clinical validation for CogniMIR®                                                                                |
| ● | the terms and timing of any future collaboration, licensing, or other arrangements that DiamiR may establish;       |
| ● | the outcome, timing, and cost of meeting regulatory requirements;                                                   |
| ● | the cost of obtaining, maintaining, defending, and enforcing intellectual property rights, including patent rights; |
| ● | the effect of competing technological and market developments;                                                      |
| ● | market acceptance of CogniMIR® if DiamiR meets regulatory requirements for its commercialization; and               |
| ● | the extent to which DiamiR acquires, licenses, or invests in businesses, products or technologies.                  |

Until DiamiR can generate a sufficient amount of revenue from CogniMIR
and related services and products, if ever, DiamiR expects to finance future cash needs through public or private equity offerings, debt
financings or grants. Additional funds may not be available when needed on terms that are acceptable to DiamiR, or at all. If adequate
funds are not available, DiamiR may be required to delay, reduce the scope of or eliminate our commercialization efforts. To the extent
that DiamiR raises additional funds by issuing shares of common stock, its shareholders may experience additional dilution, and debt financing,
if available, may involve restrictive covenants. To the extent that DiamiR raises additional funds through collaborations and licensing
arrangements, it may be necessary to relinquish some rights to its technologies or its product candidates or grant licenses on terms that
may not be favorable to DiamiR. DiamiR may seek